Frontiers in Pharmacology | Experimental Pharmacology and Drug Discovery

Brief Research Report

Published on 19 Feb 2025

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

in Experimental Pharmacology and Drug Discovery

Petra Molnár
Máté Ágoston Demény
Beáta Várkonyi
Zsuzsanna Polgár
Ágnes Pór
Ilona Kovács
Andrea Szegedi
Attila Gábor Szöllősi
Magdolna Szántó

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1519066

122 views

Original Research

Published on 19 Feb 2025

Harnessing machine learning and AI-driven analytics to identify novel drug targets and predict chemotherapy efficacy in NSCLC

in Experimental Pharmacology and Drug Discovery

Shaojia Qin
Biyu Deng
Dan Mo
Zhengyou Zhang
Xuan Wei
Zhougui Ling

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1555040

163 views

Original Research

Published on 19 Feb 2025

Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head

in Experimental Pharmacology and Drug Discovery

Jie Xu
Wei Deng
Xun Zhu
Deyu Han
Yu Zheng
Qun Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1508971

Systematic Review

Accepted on 18 Feb 2025

Prognostic and clinicopathological roles of circular RNA expression in chemoresistance in head and neck squamous cell carcinoma: A systematic review

in Experimental Pharmacology and Drug Discovery

Sayan Kumar Das
Sameer Khasbage
Ashim Mishra
Babban Jee

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1502107

Original Research

Published on 18 Feb 2025

Mechanism of PAVA-induced toxicity and inflammation in a cocultured skin cell model

in Experimental Pharmacology and Drug Discovery

Yunyang Song
Wenjie Cheng
Zhen Wang
Tianqi Zhou
Fanghui Wu
Yifeng Yin
Dan Xu
Yanli Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531459

Original Research

Published on 18 Feb 2025

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

in Experimental Pharmacology and Drug Discovery

Qi Yang
Dan Zhao
Linjie Ju
Peng Cao
Jifu Wei
Zhixian Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1524277

103 views

Original Research

Accepted on 17 Feb 2025

Adverse event profile of Lomustine and Temozolomide : a descriptive analysis from WHO-VigiAccess

in Experimental Pharmacology and Drug Discovery

Hua Luo
Shaohua Fan
Lu Liang
Youfu He
Jiangjie Chen
Chenghao Xu
Jing Zhu
Liwei Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1534802

Original Research

Accepted on 17 Feb 2025

Antimicrobial Photodynamic Therapy with 5-Aminolevulinic Acid plus Antibiotics: A Promising Treatment for Tibial Osteomyelitis Caused by Drug-resistant Bacteria

in Experimental Pharmacology and Drug Discovery

Ju Zuo
Feiyan Kong
Xiyu Wang
Tianyu Wang
Jianxi Zhao
Zhanjuan Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1566744

Review

Accepted on 17 Feb 2025

Recent Advances in the Multifaceted Mechanisms of Catalpol in Treating Osteoporosis

in Experimental Pharmacology and Drug Discovery

Na Li
Xiaoying Mu
Shudong Zhang
Huaxin Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1560715

Original Research

Accepted on 17 Feb 2025

FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry

in Experimental Pharmacology and Drug Discovery

Manisha Singh
Shruthi Shanmukha
Raghda Eldesouki
Maged M. Harraz

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1537912

Original Research

Accepted on 17 Feb 2025

Predicting protein-protein interactions in microbes associated with cardiovascular disease using deep denoising autoencoders and evolutionary information

in Experimental Pharmacology and Drug Discovery

Yang Li
Senyu Zhou
Jian Luo
Mei Tang
Chaojun Li
Wenhua He

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1565860

Original Research

Accepted on 17 Feb 2025

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

in Experimental Pharmacology and Drug Discovery

Yawei Tian
Huiming Liu
Xiaoxue Bao
Yukun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1539411

Original Research

Accepted on 17 Feb 2025

PDP1 related ferroptosis risk signature indicates distinct immune microenvironment and prognosis of breast cancer patients

in Experimental Pharmacology and Drug Discovery

Huifen Dang
Gongjian Zhu
Chen Gao
Yingxia Tian
Yingxia Tian

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1551325

Original Research

Accepted on 14 Feb 2025

Obesity promotes immunotherapy efficacy by up-regulating the glycolyticmediated histone lactacylation modification of CD8+ T cells

in Experimental Pharmacology and Drug Discovery

Xinghao Ai
Kaixuan Wang
Dongmin Shi
Jingyuan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533464

Original Research

Published on 14 Feb 2025

Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma

in Experimental Pharmacology and Drug Discovery

Haoyu Xu
Senlin Peng
Junwu Li
Yuanyuan Bai
Guozhi Zhao
Simin Liang
Wei Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1531056

225 views

Original Research

Published on 14 Feb 2025

Unveiling the effects of Rosa canina oligosaccharide liposome on neuropathic pain and motor dysfunction following spinal cord injury in rats: relevance to its antioxidative effects

in Experimental Pharmacology and Drug Discovery

Yasaman Ahmadpour
Gholamreza Bahrami
Elham Arkan
Fatemeh Abbaszadeh
Faranak Aghaz
Sajad Fakhri
Javier Echeverría

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1533025

181 views

Navigation group

Articles

The clinically applied PARP inhibitor talazoparib ameliorates imiquimod-induced psoriasis in mice without reducing skin inflammation

Harnessing machine learning and AI-driven analytics to identify novel drug targets and predict chemotherapy efficacy in NSCLC

Potential efficacy and mechanisms of icariin for the animal model of osteonecrosis of the femoral head

Prognostic and clinicopathological roles of circular RNA expression in chemoresistance in head and neck squamous cell carcinoma: A systematic review

Mechanism of PAVA-induced toxicity and inflammation in a cocultured skin cell model

Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells

Adverse event profile of Lomustine and Temozolomide : a descriptive analysis from WHO-VigiAccess

Antimicrobial Photodynamic Therapy with 5-Aminolevulinic Acid plus Antibiotics: A Promising Treatment for Tibial Osteomyelitis Caused by Drug-resistant Bacteria

Recent Advances in the Multifaceted Mechanisms of Catalpol in Treating Osteoporosis

FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry

Predicting protein-protein interactions in microbes associated with cardiovascular disease using deep denoising autoencoders and evolutionary information

Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway

PDP1 related ferroptosis risk signature indicates distinct immune microenvironment and prognosis of breast cancer patients

Obesity promotes immunotherapy efficacy by up-regulating the glycolyticmediated histone lactacylation modification of CD8+ T cells

Zebularine showed anti-tumor efficacy in clear cell renal cell carcinoma

Unveiling the effects of Rosa canina oligosaccharide liposome on neuropathic pain and motor dysfunction following spinal cord injury in rats: relevance to its antioxidative effects